Axsome Therapeutics (AXSM) Change in Account Payables (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Change in Account Payables data on file, last reported at $41.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 201.31% year-over-year to $41.2 million; the trailing twelve-month figure through Mar 2026 stood at $21.0 million (down 33.97% YoY), and the FY2025 full-year result was -$6.5 million, down 120.63% from the prior year.
• Change in Account Payables grew to $41.2 million in Q1 2026, from $11.3 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $41.2 million in Q1 2026 to a low of -$37.4 million in Q3 2025.
• A 5-year average of $5.5 million and a median of $7.2 million in 2023 frame the typical range for Change in Account Payables.
• Across the five-year window, Change in Account Payables surged 11172.43% in 2022 and slumped 1383.93% in 2025, its largest moves.
• Tracing AXSM's Change in Account Payables over 5 years: stood at $25.8 million in 2022, then sank by 55.04% to $11.6 million in 2023, then sank by 33.13% to $7.7 million in 2024, then surged by 46.05% to $11.3 million in 2025, then soared by 263.97% to $41.2 million in 2026.
• Business Quant data shows AXSM's Change in Account Payables at $41.2 million in Q1 2026, $11.3 million in Q4 2025, and -$37.4 million in Q3 2025.